Spots Global Cancer Trial Database for Time to Initiated Antitumor Therapy for Tumor Patients With COVID19 Infection

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Time to Initiated Antitumor Therapy for Tumor Patients With COVID19 Infection

Official Title: When to Initiation Antitumor Therapy for Tumor Patients With COVID19 Infection

Study ID: NCT06006845

Conditions

Tumor

COVID-19

Interventions

Study Description

Brief Summary: The goal of this observational study is to study the safety of initiation of antitumor therapy early after nucleic acid test turn negativity in tumor patients infected with COVID-19. The main questions aims to answer are: * Whether initiation of antitumor therapy early after nucleic acid test turn negativity in tumor patients infected with COVID-19 increases adverse events related to antitumor therapy. * Whether initiation of antitumor therapy early after nucleic acid test turn negativity in tumor patients infected with COVID-19 increases risk of re-infection of COVID-19. * How initiation of antitumor therapy early after nucleic acid test turn negativity in tumor patients infected with COVID-19 affects QoL of tumor patients Participants will be asked to answer the question about: * the severity and duration of COVID-19 symptoms * the date of diagnosis of COVID-19 * the date of negative nucleic acid test * the QoL of life before infection with COVID-19, during infection of COVID-19, after nucleic acid test negativity and receiving antitumor therapy

Detailed Description: